SCHEMBL3706706

SCHEMBL3706706

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(Br)c(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
ALOX15 P16050 5/20 0.58
LMNA P02545 1/20 0.58
USP7 Q93009 1/20 0.58
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 3/20 0.56
POLB P06746 1/20 0.56
TP53 P04637 1/20 0.55
MDM2 Q00987 1/20 0.55
HPGD P15428 2/20 0.55
FPR1 P21462 3/20 0.54
GAA P10253 4/20 0.53
HSD17B10 Q99714 1/20 0.53
HTT P42858 3/20 0.52
TSHR P16473 2/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705034 0.90 USP7 (0.59) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3710756 0.90 USP7 (0.63) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3705340 0.87 MEN1 (0.78) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3705035 0.84 KDM4E (0.66) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3716653 0.84 USP7 (0.70) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3707576 0.83 KDM4E (0.64) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL16904821 0.83 KDM4E (0.64) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3713778 0.82 KDM4E (0.63) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3704381 0.82 MEN1 (0.70) MEN1KMT2AALOX15LMNAUSP7
SCHEMBL3709852 0.82 MEN1 (0.59) MEN1KMT2AALOX15LMNAUSP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed